Empagliflozin improves cardiac energetics during ischaemia/reperfusion by directly increasing cardiac ketone utilization
{{output}}
Aims: Empagliflozin (EMPA), a potent inhibitor of the renal sodium-glucose cotransporter 2 and an effective treatment for Type 2 diabetes, has been shown to have cardioprotective effects, independent of improved glycaemic control... ...
